ES2525353T3 - Derivado de espiroimidazolona - Google Patents
Derivado de espiroimidazolona Download PDFInfo
- Publication number
- ES2525353T3 ES2525353T3 ES10769728T ES10769728T ES2525353T3 ES 2525353 T3 ES2525353 T3 ES 2525353T3 ES 10769728 T ES10769728 T ES 10769728T ES 10769728 T ES10769728 T ES 10769728T ES 2525353 T3 ES2525353 T3 ES 2525353T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- atoms
- halogen atom
- atom
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto representado por las siguientes fórmulas generales (1) o (2):**Fórmula** o una sal farmacológicamente aceptable de un compuesto representado por las fórmulas (1) o (2): [donde en la fórmula general (1) W se selecciona de: 1) un enlace simple, 2) alquileno C1-C10 que contiene opcionalmente un grupo carbonilo, donde el alquileno está opcionalmente sustituido con un átomo o átomos de halógeno y/o un grupo o grupos hidroxilo, 3) alquenileno C2-C10 opcionalmente sustituido con un átomo o átomos de halógeno, 4) alquinileno C2-C10, 5) arileno opcionalmente sustituido con un átomo o átomos de halógeno, 6) heteroarileno opcionalmente sustituido con un átomo o átomos de halógeno, 7) heteroalquileno C2-C10 opcionalmente sustituido con un átomo o átomos de halógeno, 8) -NH-, -NHCH2- o -NHCH2CH2-, 9) cicloalquileno y 10) -(cicloalquileno)-CH2-; X se selecciona entre el enlace o los grupos siguientes: 1) un enlace simple, 2) alquileno C1-C10 opcionalmente sustituido con un átomo o átomos de halógeno o cicloalquilo, 3) alquenileno C2-C10 opcionalmente sustituido con un átomo o átomos de halógeno, 4) alquinileno C2-C10 opcionalmente sustituido con un átomo o átomos de halógeno, 5) oxialquileno C1-C10 opcionalmente sustituido con un átomo o átomos de halógeno y 6) -NR47- donde R47 se selecciona entre: i) un átomo de hidrógeno y ii) alquilo C1-C10 opcionalmente sustituido con un átomo o átomos de halógeno; Y se selecciona de: 1) un átomo de oxígeno, 2) un átomo de azufre y 3) >=NR37, o 731 4) Y es -NR38R39 mostrado en la siguiente fórmula (A):**Fórmula**
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009109256 | 2009-04-28 | ||
| JP2009109256 | 2009-04-28 | ||
| PCT/JP2010/057432 WO2010126030A1 (ja) | 2009-04-28 | 2010-04-27 | スピロイミダゾロン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2525353T3 true ES2525353T3 (es) | 2014-12-22 |
Family
ID=43032174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10769728T Active ES2525353T3 (es) | 2009-04-28 | 2010-04-27 | Derivado de espiroimidazolona |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9169254B2 (es) |
| EP (1) | EP2433940B9 (es) |
| JP (1) | JP5671453B2 (es) |
| CY (1) | CY1115744T1 (es) |
| DK (1) | DK2433940T3 (es) |
| ES (1) | ES2525353T3 (es) |
| HR (1) | HRP20141126T1 (es) |
| PL (1) | PL2433940T3 (es) |
| PT (1) | PT2433940E (es) |
| SI (1) | SI2433940T1 (es) |
| TW (1) | TWI496782B (es) |
| WO (1) | WO2010126030A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI496782B (zh) | 2009-04-28 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | Spiro haloperidone derivatives |
| AU2011312490B2 (en) * | 2010-09-28 | 2015-06-25 | Radius Pharmaceuticals, Inc. | Selective androgen receptor modulators |
| ES2464598T3 (es) | 2011-07-22 | 2014-06-03 | Université Joseph Fourier | Nuevos derivados bis-indólicos, procedimiento para su preparación, y sus utilizaciones como fármaco |
| MY178583A (en) * | 2012-12-10 | 2020-10-16 | Chugai Pharmaceutical Co Ltd | Hydantoin derivative |
| JP6290138B2 (ja) * | 2014-06-09 | 2018-03-07 | 中外製薬株式会社 | ヒダントイン誘導体含有医薬組成物 |
| MX371090B (es) * | 2014-06-09 | 2020-01-16 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica que contiene derivado de hidantoina. |
| TWI686392B (zh) * | 2014-06-09 | 2020-03-01 | 日商中外製藥股份有限公司 | 含有乙內醯脲衍生物之醫藥組合物 |
| EP3286172B1 (en) | 2015-04-23 | 2019-06-12 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitors and uses thereof |
| CN105017252B (zh) * | 2015-06-30 | 2017-04-12 | 河南师范大学 | 具有生物活性的1,3,8‑三氮杂螺[4,5]癸烷‑2‑胍‑4‑酮类化合物及其制备方法和应用 |
| WO2017223115A1 (en) | 2016-06-22 | 2017-12-28 | Radius Health, Inc. | Ar+ breast cancer treatment methods |
| LT3532459T (lt) | 2016-10-26 | 2023-11-10 | Constellation Pharmaceuticals, Inc. | Lsd1 inhibitoriai ir jų medicininis panaudojimas |
| WO2018086993A1 (en) * | 2016-11-14 | 2018-05-17 | Synthon Biopharmaceuticals B.V. | PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES |
| IT201600130729A1 (it) * | 2016-12-23 | 2018-06-23 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione degli intermedi del delmopinolo |
| CN108003037B (zh) * | 2018-01-18 | 2020-07-24 | 上海仁实医药科技有限公司 | 一种n-甲基-5-己烯-1-胺的合成工艺 |
| EP3590927A1 (en) | 2018-07-05 | 2020-01-08 | Bayer Animal Health GmbH | Novel compounds for controlling arthropods |
| AU2019313853A1 (en) | 2018-07-30 | 2021-03-04 | Chugai Seiyaku Kabushiki Kaisha | Solid dispersion of hydantoin derivative |
| CN116997551A (zh) * | 2020-10-12 | 2023-11-03 | 密歇根大学董事会 | Egfr调节剂的合成 |
| CN112142634A (zh) * | 2020-11-02 | 2020-12-29 | 广州市科虎生物技术研究开发中心 | 一种（2-羧乙基）二甲基氯化锍的制备方法 |
| CN112574226A (zh) * | 2020-12-15 | 2021-03-30 | 海门华祥医药科技有限公司 | 5,6-亚甲基二氧基吲哚的制备方法 |
| CN114409569A (zh) * | 2021-12-23 | 2022-04-29 | 江苏长青农化股份有限公司 | 一种手性稻瘟酰胺的制备方法 |
| TW202440065A (zh) | 2022-12-28 | 2024-10-16 | 日商中外製藥股份有限公司 | 包含分散對象物質的固體分散體、包含其之醫藥組合物及其製造方法 |
| CN116969831B (zh) * | 2023-08-01 | 2025-09-23 | 菏泽皓元医药科技有限公司 | 一种莫奈太尔的中间体及其制备方法 |
| CN117263810B (zh) * | 2023-09-19 | 2026-01-27 | 上海凌凯科技股份有限公司 | 还原硝基苯制备苯胺类化合物以及选择性碘代苯胺类化合物的方法 |
| WO2025226892A1 (en) * | 2024-04-24 | 2025-10-30 | Septerna, Inc. | Spirocycle-containing diaminomethylene pyrimidine-2,4,6-trione agonists of parathyroid hormone 1 and incretin receptors |
| TW202606695A (zh) * | 2024-04-24 | 2026-02-16 | 美商塞普特納公司 | 含有取代或修飾的二胺基亞甲基嘧啶—２，４，６—三酮的副甲狀腺素１受體和腸促胰島素受體的激動劑 |
| WO2026107328A1 (en) * | 2024-11-15 | 2026-05-21 | Septerna, Inc. | Agonists of parathyroid hormone 1 and incretin receptors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1135470A (ja) | 1997-07-23 | 1999-02-09 | Teijin Ltd | ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤 |
| CN1132819C (zh) | 1998-12-11 | 2003-12-31 | 霍夫曼-拉罗奇有限公司 | 作为TNF－α抑制剂的环状肼衍生物 |
| WO2002017911A1 (en) | 2000-08-30 | 2002-03-07 | Teijin Limited | Parathyroid hormone production inhibitors containing vitamin d3 derivatives |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| EP1713815A4 (en) | 2004-02-11 | 2009-03-11 | Smithkline Beecham Corp | PTH AGONISTS |
| WO2005077918A1 (en) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US7659264B2 (en) | 2004-10-07 | 2010-02-09 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| WO2007135417A1 (en) | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| WO2007149873A2 (en) | 2006-06-20 | 2007-12-27 | Wyeth | Kv1.5 potassium channel inhibitors |
| DE602008003221D1 (de) * | 2007-06-07 | 2010-12-09 | Hoffmann La Roche | Prolinamidderivate als nk3-antagonisten |
| BRPI0820669A2 (pt) * | 2007-12-10 | 2020-08-04 | Novartis Ag | compostos orgânicos |
| US7981904B2 (en) * | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| EP2349325B1 (en) | 2008-10-13 | 2018-05-30 | University Of Rochester | Teriparatide for use for promoting repair of articular cartilage |
| TWI496782B (zh) | 2009-04-28 | 2015-08-21 | Chugai Pharmaceutical Co Ltd | Spiro haloperidone derivatives |
| MY178583A (en) | 2012-12-10 | 2020-10-16 | Chugai Pharmaceutical Co Ltd | Hydantoin derivative |
-
2010
- 2010-04-27 TW TW099113235A patent/TWI496782B/zh active
- 2010-04-27 ES ES10769728T patent/ES2525353T3/es active Active
- 2010-04-27 PL PL10769728T patent/PL2433940T3/pl unknown
- 2010-04-27 SI SI201030824T patent/SI2433940T1/sl unknown
- 2010-04-27 WO PCT/JP2010/057432 patent/WO2010126030A1/ja not_active Ceased
- 2010-04-27 PT PT107697286T patent/PT2433940E/pt unknown
- 2010-04-27 US US13/266,517 patent/US9169254B2/en active Active
- 2010-04-27 HR HRP20141126AT patent/HRP20141126T1/hr unknown
- 2010-04-27 EP EP10769728.6A patent/EP2433940B9/en active Active
- 2010-04-27 DK DK10769728.6T patent/DK2433940T3/en active
- 2010-04-27 JP JP2011511406A patent/JP5671453B2/ja active Active
-
2014
- 2014-10-23 CY CY20141100870T patent/CY1115744T1/el unknown
-
2015
- 2015-09-17 US US14/857,005 patent/US9487517B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2433940T3 (en) | 2015-01-12 |
| WO2010126030A1 (ja) | 2010-11-04 |
| PT2433940E (pt) | 2014-12-12 |
| EP2433940A4 (en) | 2012-10-10 |
| EP2433940B1 (en) | 2014-09-24 |
| EP2433940A1 (en) | 2012-03-28 |
| JPWO2010126030A1 (ja) | 2012-11-01 |
| US9487517B2 (en) | 2016-11-08 |
| CY1115744T1 (el) | 2017-01-25 |
| SI2433940T1 (sl) | 2015-01-30 |
| PL2433940T3 (pl) | 2015-03-31 |
| TWI496782B (zh) | 2015-08-21 |
| HRP20141126T1 (hr) | 2015-01-30 |
| EP2433940B9 (en) | 2015-10-28 |
| US20160016956A1 (en) | 2016-01-21 |
| JP5671453B2 (ja) | 2015-02-18 |
| US9169254B2 (en) | 2015-10-27 |
| TW201103938A (en) | 2011-02-01 |
| US20120270838A1 (en) | 2012-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6640247A2 (es) | Compuesto[5.6]heterociclico o una sal farmacológicamente aceptable del mismo útil para la prevención de enfermedades asociadas con el metabolismo óseo | |
| PY08034070A (es) | Derivados de 1, 2, 4, 5-tetrahidro -3-H- benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen. | |
| PA8783401A1 (es) | Derivados de piperidina/piperazina | |
| UY28878A1 (es) | Compuestos de aril-o heteroarilamida ortosustituidos y composiciones | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| AR093438A2 (es) | Compuestos fenolicos policiclicos como estabilizantes | |
| ECSP14020586A (es) | Composición para el control de plagas que incluye un derivado de iminopiridina novedoso | |
| EA200701176A1 (ru) | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их | |
| UY28877A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida y composiciones | |
| CO6210724A2 (es) | Compuesto heterociclico y composicion farmaceutica del mismo | |
| NI201000134A (es) | Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| CO6251235A2 (es) | Compuestos derivados de azetidinas su preparacion y su aplicacion en terapeutica | |
| AR083167A1 (es) | Derivados heterociclicos de benzamidas sustituidas, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, diabetes, obesidad y otras enfermedades neurologicas | |
| MX2011011281A (es) | Compuesto de carbinol que tiene un enlazante heterociclico. | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| AR061377A1 (es) | Derivados diazeniodiolatos, procedimiento de preparacion, composiciones farmaceuticas que los contienen y usos en patologias cardiovasculares. | |
| BR112013015604A2 (pt) | novo derivado de isoquinolina substituído | |
| CO6290668A2 (es) | Derivados de 1-oxo-1,2-dihidroisoquinolein-5-carboxamidas y de 4-oxo-3,4-dihifroquinazolina -8-carboxamidas su preparacion y su aplicacion en terapeutica | |
| EA200970002A1 (ru) | Двойственные молекулы, содержащие пероксидное производное, их синтез и их терапевтические применения | |
| AR045619A1 (es) | 2 - carbonilamino - 6 - piperidinaminopiridinas sustituidas y 1 - carbonilamino - 3 - piperidinaminobencenos sustituidos como agonistas de 5 - ht1f | |
| AR081720A1 (es) | Composicion para el control de plagas | |
| HN2009000504A (es) | Derivados de pirrolizina, indolizina y quinolizina su preparacion y su aplicacion en terapeutica. | |
| AR061561A1 (es) | Derivados amino de b- homoandrostanos y b- heteroandrostanos. procesos de obtencion y composiciones farmaceuticas | |
| AR053559A1 (es) | Compuestos derivados antibacterianos de 2,4' -dihidroxifenilo 3',5-disustituidos y metodos relacionados |